Edgewise Therapeutics (EWTX) Total Non-Current Liabilities (2021 - 2022)
Edgewise Therapeutics (EWTX) posted Total Non-Current Liabilities of $10.9 million for Q2 2022, down 11.06% sequentially from $12.2 million in Q1 2022.
Powered by 
Analysis
Edgewise Therapeutics (EWTX) Total Non-Current Liabilities (2021 - 2022) Analysis & Trends
Edgewise Therapeutics has reported Total Non-Current Liabilities for 2 years, with the latest figure at $10.9 million in Q2 2022.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $10.9 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $10.9 million (changed N/A YoY) and the FY2021 annual result came in at $10.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities declined to $10.9 million in Q2 2022 per EWTX's latest filing, from $12.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $12.2 million in Q1 2022 and troughed at $8.8 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Edgewise Therapeutics | 4.65 Bn | 4.65 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 10.85 Mn |
| Mar 31, 2022 | 12.20 Mn |
| Dec 31, 2021 | 10.52 Mn |
| Sep 30, 2021 | 8.75 Mn |